iAB Financial Bank decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,892 shares of the medical instruments supplier’s stock after selling 83 shares during the period. iAB Financial Bank’s holdings in Becton, Dickinson and were worth $369,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in BDX. Waldron LP acquired a new stake in Becton, Dickinson and in the 1st quarter valued at about $383,000. Advisory Services Network LLC acquired a new stake in Becton, Dickinson and in the 1st quarter valued at about $2,280,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Becton, Dickinson and by 2.5% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 37,268 shares of the medical instruments supplier’s stock valued at $6,836,000 after acquiring an additional 903 shares during the last quarter. Geneva Advisors LLC raised its holdings in Becton, Dickinson and by 0.8% in the 1st quarter. Geneva Advisors LLC now owns 392,781 shares of the medical instruments supplier’s stock valued at $72,052,000 after acquiring an additional 3,192 shares during the last quarter. Finally, Willingdon Wealth Management raised its holdings in Becton, Dickinson and by 1.8% in the 1st quarter. Willingdon Wealth Management now owns 15,282 shares of the medical instruments supplier’s stock valued at $2,803,000 after acquiring an additional 276 shares during the last quarter. Institutional investors own 87.12% of the company’s stock.

A number of research firms have commented on BDX. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price objective (up previously from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a report on Monday, July 17th. Finally, Cowen and Company reiterated a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $196.93.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the completion of the transaction, the insider now owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the transaction, the insider now directly owns 26,638 shares of the company’s stock, valued at approximately $5,279,917.98. The disclosure for this sale can be found here. Insiders have sold 75,904 shares of company stock valued at $15,242,688 in the last ninety days. 1.40% of the stock is currently owned by company insiders.

Shares of Becton, Dickinson and Company (NYSE:BDX) opened at 194.00 on Thursday. The company has a 50-day moving average of $199.01 and a 200 day moving average of $191.58. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $206.63. The firm has a market cap of $44.15 billion, a P/E ratio of 56.18 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the prior year, the business posted $2.35 earnings per share. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities research analysts anticipate that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be given a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.51%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

COPYRIGHT VIOLATION WARNING: “iAB Financial Bank Sells 83 Shares of Becton, Dickinson and Company (BDX)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/iab-financial-bank-sells-83-shares-of-becton-dickinson-and-company-bdx/1577107.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.